Success of BioNTech-Pfizer COVID-19 vaccine shifts focus to deployment, additional vaccines

An FDA advisory committee is expected to recommend authorization of an mRNA COVID-19 vaccine from Pfizer and BioNTech Thursday, setting the stage for a greenlight from the agency and shifting the pandemic response focus in the U.S. to deployment.

The committee will be briefed on plans of Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) to collect sufficient data to gain full approval of BNT162b2, as well as on strategies for testing additional vaccine candidates when the public has access to vaccines that have received emergency use authorizations of BLAs. ...